Following Gunst’s last BABY Sell transaction on June 12, 2015, the stock climbed by 3.5%.
Based on Natus Medical Inc.`s latest earnings report from March 31, the company posted quarterly revenue of $89.4M and quarterly net profit of $8.6M. In comparison, last year the company earned revenue of $86.33M and had a net profit of $7.74M. The company has a one year high of $46.98 and a one year low of $27. BABY’s market cap is $1.52B and the company has a P/E ratio of 41.3%.
Looking at blogger coverage of BABY, there is a 100% Bullish tendency on the stock, in relation to a 67% average bullish tendency within the Healthcare sector.
Over the last 3 months, the insider sentiment on Natus Medical Inc has been neutral based on 46 corporate insider transactions. This sentiment is higher than the average sector sentiment of insiders.
Natus Medical Inc provides newborn care & neurology healthcare products & services used for screening, diagnosis, detection, treatment, monitoring & tracking of medical ailments in newborn care, epilepsy, sleep disorders, and balance & mobility disorders.